Open-label, Non-randomised, Single-centre, Multiple-dose, Phase 1, Pharmacokinetic Trial With a Topical Formulation of Tacrolimus in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Allergic conjunctivitis; Atopic dermatitis; Coronary artery restenosis; Eye disorders; Graft-versus-host disease; Interstitial lung diseases; Intestinal transplant rejection; Lupus nephritis; Myasthenia gravis; Open-angle glaucoma; Psoriasis; Rheumatoid arthritis; Transplant rejection; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 15 Apr 2019 Status changed from recruiting to completed.
- 20 Feb 2019 Planned End Date changed from 1 Nov 2018 to 1 Feb 2019.
- 20 Feb 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Feb 2019.